Please login to the form below

Not currently logged in

TEVA buys Mexico’s RIMSA for $2.3bn

Follows acquisition ofAllergan’s generic drugs business

TEVA has bought Mexican drug manufacturer Representaciones e Investigaciones Médicas SA (RIMSA) for $2.3bn.

The acquisition comes a few months after the Israeli-based firm agreed to buy Allergan's generics for $40.5bn, further consolidating its position as the world's number one generic drug manufacturer.

Erez Vigodman, president and CEO of TEVA, said: “This acquisition delivers on our strategy of increasing our presence in key emerging markets in order to position TEVA for long-term growth.

“Rimsa will provide… the strong Rimsa brand, licensed portfolio of differentiated, patent-protected products, promising pipeline, significant relationships with physicians, patients and healthcare providers and its strong commercial presence.”

Rimsa had revenue of $227m in 2014 with annual growth rate of over 10.6% since 2011 and TEVA expects the deal to close in early 2016.

Luis Jorge Pérez Juarez, CEO of Rimsa, said: “We share TEVA's focus on providing quality healthcare and we are excited to be a part of TEVA in meeting the needs of a population of 120m.”

In August, TEVA also bought a 51% share in Immuneering, a genomic analysis company, as part of a drive to develop personalised medicines for central nervous system diseases.

TEVA's acquisition of Allergan involved the Israeli firm paying $33.8bn in cash as well as shares of TEVA, valued at $6.8bn. The purchase meant TEVA's long-term pursuit of generics company Mylan was ended as it fought to stop takeover.

According to GlobalData, Mexico's healthcare market value will be worth approximately $28bn by 2020, growing from $17.6bn in 2013. 

TEVA's annual revenue in 2014 was $18.3bn and it currently has a programme in place to reduce expenses by $1.3bn by the end of 2017. 

Article by
Nikhil Patel

2nd October 2015

From: Sales



Subscribe to our email news alerts


Add my company
Evoke Mind+Matter

We are Evoke Mind ‘PLUS’ Matter. The ‘plus’ is important to us because we are all about offering more for...

Latest intelligence

Rare diseases: not so rare after all
The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...